{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:17:59Z","timestamp":1783117079790,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014996","name":"Health Commission of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY494"],"award-info":[{"award-number":["2021KY494"]}],"id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015258","name":"Zhejiang Provincial People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.heliyon.2023.e19154","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T22:14:49Z","timestamp":1692396889000},"page":"e19154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt\/mTOR\/p70S6k-4EBP-1 and c-Raf7MEK\/ERK signaling pathways"],"prefix":"10.1016","volume":"9","author":[{"given":"Ligang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songcheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2023.e19154_bib1","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G. Ital. Nefrol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/his.13735","article-title":"Grading of renal cell carcinoma","volume":"74","author":"Delahunt","year":"2019","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.18632\/aging.102660","article-title":"Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma","volume":"12","author":"Xu","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19154_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00595-021-02429-9","article-title":"Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus","volume":"52","author":"Yuan","year":"2022","journal-title":"Surg. Today"},{"key":"10.1016\/j.heliyon.2023.e19154_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108623","article-title":"Metabolomics in renal cell carcinoma: from biomarker identification to pathomechanism insights","volume":"695","author":"Chen","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib6","article-title":"Metabolic reprogramming in renal cancer: events of a metabolic disease","volume":"1876","author":"Chakraborty","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.heliyon.2023.e19154_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1533033821997834","article-title":"Long non-coding RNA LOC648987 promotes proliferation and metastasis of renal cell carcinoma by regulating epithelial-mesenchymal transition","volume":"20","author":"Su","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19154_bib8","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20204421","article-title":"Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology","volume":"41","author":"Zheng","year":"2021","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e19154_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrurol.2017.123","article-title":"Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials","volume":"14","author":"Blick","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19154_bib10","first-page":"875","article-title":"Image interpretation: practical triage of benign from malignant renal masses","volume":"58","author":"Allgood","year":"2020","journal-title":"Radiol. Clin."},{"key":"10.1016\/j.heliyon.2023.e19154_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105732","article-title":"New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","volume":"170","author":"He","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2023.e19154_bib12","article-title":"Chinese medicine leptochloa chinensis inhibits the malignant behaviors of renal cell carcinoma 786-O cells by regulating the mTOR pathway","volume":"2021","author":"Tan","year":"2021","journal-title":"Evid. Bas. Comp. Alter. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19154_bib13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jsfa.10152","article-title":"Resveratrol: a review of plant sources, synthesis, stability, modification and food application","volume":"100","author":"Tian","year":"2020","journal-title":"J. Sci. Food Agric."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19154_bib14","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cam4.2108","article-title":"Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science","volume":"8","author":"Xiang","year":"2019","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib15","first-page":"13","article-title":"Health benefits of resveratrol administration","volume":"66","author":"Galiniak","year":"2019","journal-title":"Acta Biochim. Pol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19154_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clinbiochem.2012.11.029","article-title":"Proteomics and the search for biomarkers for renal cancer","volume":"46","author":"Craven","year":"2013","journal-title":"Clin. Biochem."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19154_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clgc.2020.07.001","article-title":"The 2020 kidney cancer treatment sequence issue","volume":"18","author":"Hsieh","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19154_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ucl.2020.07.009","article-title":"An overview of current therapeutic approaches","volume":"47","author":"Chowdhury","year":"2020","journal-title":"Urol. Clin."},{"key":"10.1016\/j.heliyon.2023.e19154_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1062504","article-title":"Burden of kidney cancer and attributed risk factors in China from 1990 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Public Health"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib20","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41467-022-29577-x","article-title":"A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population","volume":"13","author":"Qu","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19154_bib21","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1159\/000524097","article-title":"Interleukin-2 and interferon-\u03b1 for advanced renal cell carcinoma: patient outcomes, sexual dimorphism of responses, and multimodal treatment approaches over a 30-year period","volume":"106","author":"Bonetti","year":"2022","journal-title":"Urol. Int."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19154_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/0284186X.2018.1433324","article-title":"A randomized phase II trial of interleukin-2 and interferon-\u03b1 plus bevacizumab versus interleukin-2 and interferon-\u03b1 in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1","volume":"57","author":"Donskov","year":"2018","journal-title":"Acta Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19154_bib23","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA A Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.heliyon.2023.e19154_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194712","article-title":"Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment","volume":"20","author":"B\u00e6k M\u00f8ller","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib25","article-title":"A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19154_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120877","article-title":"A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e19154_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.semcancer.2019.06.011","article-title":"Unraveling the molecular mechanisms and the potential chemopreventive\/therapeutic properties of natural compounds in melanoma","volume":"59","author":"Fontana","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19154_bib28","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/10408398.2016.1263597","article-title":"Resveratrol as an anti-cancer agent: a review","volume":"58","author":"Rauf","year":"2018","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.heliyon.2023.e19154_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19154_bib30","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/leu.2008.58","article-title":"Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation","volume":"22","author":"Zhao","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19154_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1029703","article-title":"Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development","volume":"4","author":"Chen","year":"2015","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19154_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.gde.2009.11.004","article-title":"Inflammation and oncogenesis: a vicious connection","volume":"20","author":"Grivennikov","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19154_bib33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1alpha\/VEGF-A Axis in cytotoxic T cells regulates tumor progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e19154_bib34","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/cells8121593","article-title":"Natural naphthohydroquinone dimer rubioncolin C exerts anti-tumor activity by inducing apoptotic and autophagic cell death and inhibiting the NF-\u03baB and akt\/mTOR\/P70S6K pathway in human cancer cells","volume":"8","author":"Wang","year":"2019","journal-title":"Cells"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023063624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023063624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:31:23Z","timestamp":1783114283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023063624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2405844023063624"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19154","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt\/mTOR\/p70S6k-4EBP-1 and c-Raf7MEK\/ERK signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e19154"}}